Dr. Jeffrey R. Jay, M.D.
Latest statistics and disclosures from Great Point Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APGE, AMLX, ZURA, IRON, RAPT, and represent 35.31% of Great Point Partners's stock portfolio.
- Added to shares of these 10 stocks: IRON (+$20M), RAPT (+$20M), VOR (+$18M), KALV (+$11M), CTNM (+$9.1M), FULC (+$9.0M), SLNO (+$8.1M), RARE (+$6.9M), CGEM (+$6.6M), IMVT (+$6.4M).
- Started 12 new stock positions in RAPT, EVMN, KALV, FULC, RARE, VOR, IRON, SLN, CGEM, CLYM. AVTX, CTNM.
- Reduced shares in these 10 stocks: ASND (-$15M), ABVX (-$13M), CYTK (-$8.2M), XENE (-$8.0M), IONS (-$5.2M), AKRO, TSHA, DBVT, NKTR, LEGN.
- Sold out of its positions in ABSI, ABVX, AKRO, ASND, CAPR, CYTK, DBVT, HRMY, IONS, LEGN. PLRX, TSHA, XENE.
- Great Point Partners was a net buyer of stock by $59M.
- Great Point Partners has $308M in assets under management (AUM), dropping by 27.18%.
- Central Index Key (CIK): 0001281446
Tip: Access up to 7 years of quarterly data
Positions held by Dr. Jeffrey R. Jay, M.D. consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Great Point Partners
Great Point Partners holds 29 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 9.2 | $28M | +23% | 374k | 75.48 |
|
| Amylyx Pharmaceuticals (AMLX) | 6.9 | $21M | +2% | 1.8M | 12.08 |
|
| Zura Bio Class A Ord Shs (ZURA) | 6.5 | $20M | 3.8M | 5.24 |
|
|
| Disc Medicine (IRON) | 6.4 | $20M | NEW | 250k | 79.41 |
|
| Rapt Therapeutics Com New (RAPT) | 6.4 | $20M | NEW | 581k | 33.87 |
|
| Immunovant (IMVT) | 6.2 | $19M | +50% | 750k | 25.42 |
|
| Soleno Therapeutics (SLNO) | 6.0 | $19M | +77% | 400k | 46.30 |
|
| Vor Biopharma Com New (VOR) | 5.8 | $18M | NEW | 1.4M | 13.08 |
|
| Dianthus Therapeutics (DNTH) | 4.7 | $14M | +31% | 350k | 41.21 |
|
| Jade Biosciences Com New (JBIO) | 4.0 | $12M | +27% | 806k | 15.43 |
|
| Kalvista Pharmaceuticals (KALV) | 3.6 | $11M | NEW | 686k | 16.15 |
|
| Contineum Therapeutics Cl A (CTNM) | 3.0 | $9.1M | NEW | 800k | 11.43 |
|
| Eupraxia Pharmaceuticals (EPRX) | 2.9 | $9.1M | 1.2M | 7.55 |
|
|
| Fulcrum Therapeutics (FULC) | 2.9 | $9.0M | NEW | 800k | 11.31 |
|
| Nektar Therapeutics Com New (NKTR) | 2.9 | $8.9M | -29% | 211k | 42.28 |
|
| Upstream Bio (UPB) | 2.6 | $8.1M | 300k | 27.15 |
|
|
| Neurogene (NGNE) | 2.3 | $7.2M | -21% | 350k | 20.60 |
|
| Ultragenyx Pharmaceutical (RARE) | 2.2 | $6.9M | NEW | 300k | 23.00 |
|
| Context Therapeutics (CNTX) | 2.2 | $6.9M | 4.7M | 1.47 |
|
|
| Cullinan Oncology (CGEM) | 2.1 | $6.6M | NEW | 634k | 10.35 |
|
| Evommune Com Shs (EVMN) | 1.8 | $5.6M | NEW | 325k | 17.12 |
|
| Oruka Therapeutics (ORKA) | 1.8 | $5.6M | 183k | 30.31 |
|
|
| Silence Therapeutics Ads (SLN) | 1.6 | $4.9M | NEW | 808k | 6.08 |
|
| Unicycive Therapeutics Com New (UNCY) | 1.5 | $4.6M | 797k | 5.77 |
|
|
| Eliem Therapeutics (CLYM) | 1.3 | $3.9M | NEW | 980k | 4.00 |
|
| Sana Biotechnology (SANA) | 0.9 | $2.8M | 700k | 4.07 |
|
|
| Pharvaris N V (PHVS) | 0.7 | $2.3M | -46% | 83k | 27.75 |
|
| Avalo Therapeutics Com New (AVTX) | 0.7 | $2.3M | NEW | 125k | 18.16 |
|
| Rezolute Com New (RZLT) | 0.7 | $2.2M | -61% | 952k | 2.36 |
|
Past Filings by Great Point Partners
SEC 13F filings are viewable for Great Point Partners going back to 2013
- Great Point Partners 2025 Q4 filed Feb. 17, 2026
- Great Point Partners 2025 Q3 filed Nov. 14, 2025
- Great Point Partners 2025 Q2 filed Aug. 14, 2025
- Great Point Partners 2025 Q1 filed May 15, 2025
- Great Point Partners 2024 Q4 filed Feb. 14, 2025
- Great Point Partners 2024 Q3 filed Nov. 13, 2024
- Great Point Partners 2024 Q2 filed Aug. 14, 2024
- Great Point Partners 2024 Q1 filed May 15, 2024
- Great Point Partners 2023 Q4 filed Feb. 14, 2024
- Great Point Partners 2023 Q3 filed Nov. 14, 2023
- Great Point Partners 2023 Q2 filed Aug. 14, 2023
- Great Point Partners 2023 Q1 filed May 15, 2023
- Great Point Partners 2022 Q4 filed Feb. 14, 2023
- Great Point Partners 2022 Q3 filed Nov. 14, 2022
- Great Point Partners 2022 Q2 filed Aug. 15, 2022
- Great Point Partners 2022 Q1 filed May 16, 2022